Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alumis Inc. (ALMS)
NASDAQ:ALMS
Holding ALMS?
Track your performance easily
ALMS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.40 - $13.53
Previous CloseN/A
Volume29.29K
Average Volume (3M)144.36K
Market Cap
$363.44M
Enterprise Value$250.29M
Total Cash (Recent Filing)$92.86M
Total Debt (Recent Filing)$469.00K
Price to Earnings (P/E)―
Beta1.15
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.47
Shares Outstanding47,222,420
10 Day Avg. Volume183,533
30 Day Avg. Volume144,357
Standard Deviation0.10
R-Squared0.09
Alpha-0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.77
Forecast
1Y Price Target
$30.25Price Target Upside363.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Alumis Inc. News
PremiumCompany Announcements
Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive Phase 1 data for A-005 in healthy volunteers showcases ability to deliver TYK2 inhibitor across blood-brain barrier.
Drug DevelopmentESK-001 is considered a best-in-class TYK2 inhibitor with potential to surpass current market competition.
Financial OutlookManagement expects the company's cash, cash equivalents, and marketable securities of $361.9M to provide an operational runway into 2026.
Bears Say
Clinical TrialsTopline data from icotrokinra’s Phase 3 ICONIC-LEAD trial underperformed some investor expectations to observe efficacy in the range of injectable IL-23s.
Regulatory ApprovalFailure to secure regulatory approval in major markets poses a risk.
Valuation UncertaintyA-005 accounts for very little of the current valuation due to uncertainty around the validity of the mechanism and lack of in-human data.
---
Options Prices
Currently, No data available
---
Ownership Overview
61.57% Insiders
2.05% Mutual Funds
<0.01% Other Institutional Investors
32.96% Public Companies and
Individual Investors
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $6.40 and its highest was $13.53 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $363.44M.
When is Alumis Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on Aug 13, 2024. The company reported -$1.47 earnings per share for the quarter, missing the consensus estimate of -$1.46 by -$0.01.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 47,222,420 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of -$1.47 in its last earnings report, missing expectations of -$1.46. Following the earnings report the stock price went down -12.951%.
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
---
Alumis Inc. Stock Smart Score
Company Description
Alumis Inc.
Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis, and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis, for which we expect to report results in 2026 and by the end of 2024, respectively.
---
ALMS Stock 12 Month Forecast
Average Price Target
$30.25
▲(363.25% Upside)
Technical Analysis
Best Analysts Covering ALMS
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-30.85%
reiterated a buy rating 26 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -30.85% per trade.
---